<DOC>
	<DOCNO>NCT00352183</DOCNO>
	<brief_summary>Mixed combine hyperlipidemia common metabolic disorder characterize hypercholesterolemia hypertriglyceridemia . Statins fibrates complementary mechanism coadministered patient mixed hyperlipidemia . The overall objective study evaluate efficacy safety combine fenofibrate simvastatin patient mixed hyperlipidemia risk cardiovascular disease .</brief_summary>
	<brief_title>Comparison Combination Fenofibrate 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Mixed dyslipidemia Diabetes , Known hypersensitivity fenofibrate simvastatin , Pregnant lactate woman , Contraindication fenofibrate simvastatin , Unstable severe cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Hyperlipidemia Combined</keyword>
	<keyword>Combination fenofibrate simvastatin</keyword>
</DOC>